CRISPR Therapeutics AG (CRSP) FY2025 10-K Annual Report
CRISPR Therapeutics AG (CRSP) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CRISPR Therapeutics AG FY2025 10-K Analysis
Business Overview
- • Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- • New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
- • Strategic shift: Increased focus on in vivo editing pipeline using proprietary SyNTase technology and LNP delivery to target liver and other tissues, alongside advancing siRNA programs via Sirius partnership
- • Quantitative metric: CASGEVY approved in multiple countries, addressing an estimated 60,000 patients; pediatric pivotal studies show 100% efficacy in vaso-occlusive crisis and transfusion independence endpoints
- • Noteworthy fact: CASGEVY is the world’s first approved CRISPR-based gene therapy, representing a major milestone and shifting CRISPR Therapeutics from R&D to commercial-stage biopharma firm
Management Discussion & Analysis
- • No revenue or YoY revenue figures disclosed for 2025 vs 2024
- • Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
- • Investing cash flow used $31.8M in 2025 vs $280.5M in 2024, improvement driven by marketable debt securities maturities in 2025
- • Financing cash flow provided $426.0M in 2025 vs $332.0M in 2024, mainly from $397.3M ATM common shares sale and $27.7M stock option proceeds
- • Outlook: Cash sufficient to fund operations 24 months; dependency on equity/debt financing; risks include volatile markets, regulatory approval uncertainties, and commercial execution
Risk Factors
- • Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- • Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
- • Operational vulnerability: Dependence on third-party manufacturers and supply chain to establish clinical and commercial product supply capacity
- • Competitive risk: Other gene editing firms' ex vivo/in vivo therapies may trigger additional FDA requirements delaying CRISPR Therapeutics’ programs
- • Financial risk: Cash $1,975.8M as of Dec 31, 2025 sufficient for 24 months, but substantial capital raises required thereafter, diluting shareholders
CRISPR Therapeutics AG FY2025 Key Financial MetricsXBRL
Revenue
$4M
▼ -90.6% YoY
Net Income
-$582M
▼ -58.8% YoY
Operating Margin
-18933.6%
▼ -1768327bp YoY
Net Margin
-16569.8%
▼ -1558823bp YoY
ROE
-30.3%
▼ -1131bp YoY
Total Assets
$2.3B
▲ +1.0% YoY
EPS (Diluted)
$-6.47
▼ -49.1% YoY
Operating Cash Flow
-$345M
▼ -141.7% YoY
Source: XBRL data from CRISPR Therapeutics AG FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CRISPR Therapeutics AG
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.